Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Otilimab for RA disappoints in ContRAst 3
In the treatment of select patients with rheumatoid arthritis (RA), otilimab is neither better than placebo nor noninferior to sarilumab in terms of the proportion of patients achieving an American College of Rheumatology ≥20 percent response (ACR20), according to the results of the phase III ContRAst 3 study.
Otilimab for RA disappoints in ContRAst 3
25 Sep 2023
SLE rash treatment better with GC plus hydroxychloroquine combo vs GC monotherapy
Combination treatment with glucocorticoid (GC) plus hydroxychloroquine appears to yield more favourable outcomes than GC alone in the treatment of systemic lupus erythematosus (SLE) rash, while having a good safety profile, according to a study.
SLE rash treatment better with GC plus hydroxychloroquine combo vs GC monotherapy
16 Sep 2023
Which factors predict sustained RA remission with MTX or ETN monotherapy?
Following the switch from combination therapy to monotherapy, rheumatoid arthritis (RA) patients with overall lower disease activity (LDA) have higher odds of achieving and remaining in Simplified Disease Activity Index (SDAI) remission/LDA, suggests a study.
Which factors predict sustained RA remission with MTX or ETN monotherapy?
12 Sep 2023
Glucocorticoid discontinuation may prevent infection in older RA patients
For older patients with rheumatoid arthritis (RA) who are receiving glucocorticoids (GCs), stopping its use lowers the incidence of infection, according to a study.
